Tech Company Financing Transactions
Accipiter Biosciences Funding Round
Accipiter Biosciences, operating out of Seattle, raised $12.7 million in investment from Flying Fish Partners, Takeda Ventures and Alexandria Venture Investments.
Transaction Overview
Company Name
Announced On
11/7/2025
Transaction Type
Venture Equity
Amount
$12,700,000
Round
Seed
Investors
Proceeds Purpose
The company intends to use the funds to build its pipeline in immunology and oncology, further enhance its computational platform and advance up to two programs to pre-IND.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
Undisclosed
Seattle, WA Undisclosed
USA
Seattle, WA Undisclosed
USA
Phone
Undisclosed
Website
Email Address
Not Recorded
Overview
Accipiter Biosciences designs and develops de novo protein therapies -- unbound by natural limitations -- to address the world's most complex diseases. Our single-agent biologics are custom-engineered to engage multiple pathways without the limitations of traditional combination therapies.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Matthew Bick
Chief Operating Officer
William Canestaro
Chief Scientific Officer
Hector Rincon
Chief Technical Officer
Javier Castellanos
Browse more venture capital transactions:
Prev: 11/7/2025: IndustrialMind.ai venture capital transaction
Next: 11/7/2025: Comet Software venture capital transaction
Share this article
About Our Venture Capital Transactions Database
We report on all VC transactions involving tech companies. VC investment data records on this site are sourced from news reports and company announcements. The information comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs